ArticleJournal for immunotherapy of cancer2024

Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors.

Matthew H Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.